Of note, for skeletal involvement, PSMA-TV derived from PSMA PET/CT outperformed CT for correlation with BR, thereby indicating a tight link between molecular-imaging-based TV and response to prostate-cancer-specific treatment [3]. The gene discussed is FOLH1; the disease is prostate carcinoma.